IMGN632: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) OF A CD123-TARGETING ANTIBODY WITH A POTENT DNA-ALKYLATOR IS HIGHLY ACTIVE IN PRECLINICAL MODELS OF AML WITH POOR PROGNOSIS

被引：0
|
作者：
Kovtun, Y. [1 ]
Jones, G. [1 ]
Harvey, L. [1 ]
Rui, L. [1 ]
Audette, C. [1 ]
Liu, F. [1 ]
Bai, C. [1 ]
Wilhelm, A. [1 ]
Yoder, N. C. [1 ]
Adams, S. [1 ]
Goldmacher, V. S. [1 ]
Chari, R. [1 ]
Chittenden, T. [1 ]
机构：
[1] ImmunoGen Inc, Waltham, MA USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB582
引用
收藏
页码：222 / 222
页数：1
相关论文
共 50 条
  • [31] IMGN529, a Novel Antibody-Drug Conjugate (ADC) Targeting CD37 Shows Synergistic Activity with Rituximab in Non-Hodgkin Lymphoma (NHL) Models
    Deckert, Jutta
    Sloss, Callum M.
    O'Callaghan, Katie
    Tsui, Jenny
    Dawra, Nemisha
    Yi, Yong
    Coccia, Jennifer A.
    Lanieri, Leanne
    Chicklas, Sharon
    Romanelli, Angela
    BLOOD, 2015, 126 (23)
  • [32] The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations
    Whiteman, Kathleen R.
    Noordhuis, Paul
    Walker, Russell
    Watkins, Krystal
    Kovtun, Yelena
    Harvey, Lauren
    Wilhelm, Alan
    Johnson, Holly
    Schuurhuis, Gerrit Jan
    Ossenkoppele, Gert J.
    Lutz, Robert J.
    BLOOD, 2014, 124 (21)
  • [33] Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
    Challita-Eid, Pia M.
    Satpayev, Daulet
    Yang, Peng
    An, Zili
    Morrison, Karen
    Shostak, Yuriy
    Raitano, Arthur
    Nadell, Rossana
    Liu, Wendy
    Lortie, Dawn Ratay
    Capo, Linnette
    Verlinsky, Alla
    Leavitt, Monica
    Malik, Faisal
    Avina, Hector
    Guevara, Claudia I.
    Dinh, Nick
    Karki, Sher
    Anand, Banmeet S.
    Pereira, Daniel S.
    Joseph, Ingrid B. J.
    Donate, Fernando
    Morrison, Kendall
    Stover, David R.
    CANCER RESEARCH, 2016, 76 (10) : 3003 - 3013
  • [34] BYON4413, an in vivo active CD123-targeting antibody-drug conjugate, combines effectively with azacitidine and venetoclax in acute myeloid leukemia cell lines
    van der Lee, Miranda M. C.
    van Achterberg, Tanja
    Hersmus, Kaylee
    Brouwers-Vos, Annet
    van der Vleuten, Monique
    Pruis, Maurien
    Kappers, Wendy
    Verheijden, Gijs
    Huls, Gerwin
    van Wigcheren, Glenn
    Ubink, Ruud
    Sesink, Aloys
    MacInnes, Alyson
    Schuringa, Jan Jacob
    Dokter, Wim
    CANCER RESEARCH, 2024, 84 (06)
  • [35] IMGN632, a CD123-Alkylating ADC Bearing a DNA-Alkylating IGN Payload, Combines Effectively with Azacitidine and Venetoclax In Vivo, Prolonging Survival in Preclinical Models of Human Acute Myeloid Leukemia (AML)
    Kuruvilla, Vinitha Mary
    McCarthy, Rebecca
    Zhang, Qi
    Sloss, Callum M.
    Zweidler-McKay, Patrick A.
    Romanelli, Angela
    Adams, Sharlene
    Konopleva, Marina Y.
    BLOOD, 2019, 134
  • [36] DS-3939a, a novel TA-MUC1-targeting antibody-drug conjugate (ADC) with a DNA topoisomerase I inhibitor DXd, exhibits potent antitumor activity in preclinical models
    Yukiura, Mayuko
    Takano, Kohei
    Takahashi, Kazuki
    Zembutsu, Akiko
    Kitamura, Michiko
    Shiose, Yoshinobu
    Honda, Kokichi
    Oyama, Kazunori
    Obuchi, Wataru
    Yamada, Makiko
    Goto, Riki
    Sakurai, Ken
    Kumagai, Kazuyoshi
    Kagari, Takashi
    Abe, Yuki
    Agatsuma, Toshinori
    CANCER RESEARCH, 2024, 84 (06)
  • [37] Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models
    Portwood, Scott
    Puchalski, Robert A.
    Walker, Russell M.
    Wang, Eunice S.
    BLOOD, 2016, 128 (22)
  • [38] IMGN779, a CD33-Targeted Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Effector Molecule, Induces DNA Damage, Cell Cycle Arrest, and Apoptosis in AML Cells
    Krystal, Watkins M.
    Walker, Russell
    Fishkin, Nathan
    Audette, Charlene
    Kovtun, Yelena
    Romanelli, Angela
    BLOOD, 2015, 126 (23)
  • [39] IMGN853, a folate receptor (FR) a-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression
    Ab, Olga
    Bartle, Laura M.
    Sun, Xiuxia
    Wu, Rui
    Johnson, Holly A.
    Whiteman, Kathleen R.
    LaBelle, Alyssa
    Goldmacher, Victor S.
    CANCER RESEARCH, 2014, 74 (19)
  • [40] DS-6000a, a novel CDH6-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd, demonstrates potent antitumor activity in preclinical models
    Suzuki, H.
    Nagase, S.
    Saito, C.
    Nagata, M.
    Kaneda, Y.
    Honda, K.
    Nishiya, Y.
    Honda, T.
    Nakada, T.
    Goto, R.
    Ishizaka, T.
    Myobatake, Y.
    Abe, Y.
    Agatsuma, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S363 - S364
12345